Related Experiment Video
Updated: Mar 17, 2026
Evaluation of Antimicrobial Activities of Nanoparticles and Nanostructured Surfaces In Vitro
Published on: April 21, 2023
In vitro activity of ceftaroline against mecC-positive MRSA isolates
Marc Armengol-Porta1, Alberto Tenorio-Abreu2, Dirk Bandt3
1Labor Staber, Klipphausen, Germany.
Abstract:
Ceftaroline is a new cephalosporin with activity against methicillin-resistant Staphylococcus aureus (MRSA). A collection of 17 clinical and veterinary mecC-positive MRSA isolates was tested to evaluate the in vitro efficacy of ceftaroline against recently emerged mecC-MRSA isolates. Minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs) of ceftaroline for the 17 isolates were determined by broth microdilution using the methodology and interpretive criteria of the Clinical and Laboratory Standards Institute (CLSI). Additional susceptibility tests were performed using ceftaroline M.I.C.Evaluator (M.I.C.E.™) strips. All isolates showed susceptibility according to CLSI breakpoints, with MICs of ceftaroline ranging from 0.125mg/L to 0.25mg/L. MBCs were identical or up to a twofold dilution step higher. In conclusion, all tested isolates, from various sources and belonging to several clonal complexes (CCs), but predominantly to CC130, were found to be susceptible to ceftaroline. Ceftaroline could thus be an option for the treatment of mecC-MRSA infections.
Insights
Ceftaroline effectively combats mecC-positive methicillin-resistant Staphylococcus aureus (MRSA) isolates. All tested strains demonstrated susceptibility, indicating ceftaroline
Area of Science:
- Microbiology
- Infectious Diseases
- Antimicrobial Resistance
Background:
- Methicillin-resistant Staphylococcus aureus (MRSA) poses a significant threat.
- Emergence of mecC-MRSA strains presents new treatment challenges.
- Ceftaroline is a cephalosporin with known anti-MRSA activity.
Purpose of the Study:
- To evaluate the in vitro efficacy of ceftaroline against clinical and veterinary mecC-MRSA isolates.
- To determine the susceptibility of recently emerged mecC-MRSA to ceftaroline.
Main Methods:
- Broth microdilution method used to determine Minimum Inhibitory Concentrations (MICs) and Minimum Bactericidal Concentrations (MBCs).
- Clinical and Laboratory Standards Institute (CLSI) methodology and interpretive criteria were followed.
- Ceftaroline M.I.C.Evaluator (M.I.C.E.™) strips were used for additional susceptibility testing.
Main Results:
- All 17 tested mecC-MRSA isolates were susceptible to ceftaroline.
- Ceftaroline MICs ranged from 0.125 mg/L to 0.25 mg/L.
- MBCs were identical or up to twofold higher than MICs.
Conclusions:
- Ceftaroline demonstrates potent in vitro activity against a diverse collection of mecC-MRSA isolates.
- The drug is a potential therapeutic option for infections caused by these emerging MRSA strains.
- Susceptibility was observed across various clonal complexes, predominantly CC130.
More Related Videos
07:50Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
Published on: October 25, 2024
09:26Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
Published on: January 22, 2021
